Velimogene aliplasmid (Q37724340)

22 August 2017

1 reference

title

Velimogene aliplasmid (English)

1 reference

22 August 2017

Heloisa P Soares

1 reference

22 August 2017

Jose Lutzky

series ordinal

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

841-851

1 reference

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Immunotherapy of malignancy by in vivo gene transfer into tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Cancer Gene Therapy Using Plasmid DNA: Safety Evaluation in Rodents and Non-Human Primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetic Study of DNA Following Injection in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Temozolomide for the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Betting on immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481280

10.1517/14712598.2010.481280

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference